Grifols, S.A. American Depositary Shares (GRFS) Stock
Key stats
- Market cap
- $6.02B
- Price / Earnings ratio
- 12.9x
- EPS (TTM)
- $0.69
- Volume
- Loading
- 52-week high
- $9.77
- 52-week low
- $6.96
- Dividend yield
- 0.87%
- Dividend amount (latest)
- $0.17
Source: third-party data provider, as of November 13, 2026
Compare with GRFS
Recent news
Grifols Q3 Earnings Call Highlights
Grifols Q3 Earnings Call Highlights
GRFS
GRFS vs. SDZNY: Which Stock Should Value Investors Buy Now?
GRFS vs. SDZNY: Which Stock Should Value Investors Buy Now?
GRFS
Grifols says Canada plasma license suspension has no impact
Grifols says Canada plasma license suspension has no impact
GRFS
GRFS or SDZNY: Which Is the Better Value Stock Right Now?
GRFS or SDZNY: Which Is the Better Value Stock Right Now?
GRFSNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 75.22
- MACD 12/26/9
- 0.32
- EMA 9 of MACD
- 0.25
- MACD histogram
- 0.07
- SMA 50
- $7.71
- Price above SMA 50
- EMA 50
- $7.90
- Price above EMA 50
- SMA 200
- $7.98
- Price above SMA 200
- EMA 200
- $8.08
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news
Grifols Q3 Earnings Call Highlights
Grifols Q3 Earnings Call Highlights
GRFSGRFS vs. SDZNY: Which Stock Should Value Investors Buy Now?
GRFS vs. SDZNY: Which Stock Should Value Investors Buy Now?
GRFSGrifols says Canada plasma license suspension has no impact
Grifols says Canada plasma license suspension has no impact
GRFSGRFS or SDZNY: Which Is the Better Value Stock Right Now?
GRFS or SDZNY: Which Is the Better Value Stock Right Now?
GRFS
Grifols Q2 Earnings Call Highlights
Grifols Q2 Earnings Call Highlights
GRFS
Grifols approves IPO of its US biopharma business
Grifols approves IPO of its US biopharma business
GRFS
Grifols doubles net profit in 2025, driven by revenues
Grifols doubles net profit in 2025, driven by revenues
GRFS
GRFS vs. ZTS: Which Stock Is the Better Value Option?
GRFS vs. ZTS: Which Stock Is the Better Value Option?
GRFS
New Strong Sell Stocks for July 31st
New Strong Sell Stocks for July 31st
GRFS
GRFS or ZTS: Which Is the Better Value Stock Right Now?
GRFS or ZTS: Which Is the Better Value Stock Right Now?
GRFSNews tone: automated (AI) classification of the article's content, not a price prediction.
About Grifols, S.A. American Depositary Shares
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Jose Ignacio Abia Buenache | CEO & Director | 1968 |
| Mr. Rahul Srinivasan | Chief Financial Officer | 1977 |
| Mr. Lluis Pons Gomez | Senior Vice President of Strategy & COO Office | 1984 |
| Daniel Segarra | Head of Investor Relations & Sustainability and Vice President | — |
| Mr. David Ian Bell | Chief Corporate Affairs & Legal Officer | 1954 |
| Mr. Enrique de la Torre | Chief Compliance Officer | 1973 |
| Ms. Montse Ribas | Chief Communications and Reputation Officer | 1969 |
| Mr. Camille Alpi | Chief Human Resources & Talent Officer | 1981 |
| Mr. Vicente Blanquer Torre | Chief Quality Officer | 1961 |
| Mr. Ignacio Ramal Subira | Chief Internal Audit & Enterprise Risk Manager | 1968 |
Fundamentals
Valuation
Profitability
Trading
Dividend
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 75.22
- MACD 12/26/9
- 0.32
- EMA 9 of MACD
- 0.25
- MACD histogram
- 0.07
- SMA 50
- $7.71
- Price above SMA 50
- EMA 50
- $7.90
- Price above EMA 50
- SMA 200
- $7.98
- Price above SMA 200
- EMA 200
- $8.08
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $9.00
- Average
- $9.00
- High
- $9.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.3 | -11.8 | -0.1 | -4.6 | -8.5 | +11.2 | -1.8 | -5.4 | +11.0 | +3.9 |
